European Medicines Agency (EMA) Grants Orphan Drug Designation (ODD) to GC Biopharma’s Treatment for Sanfilippo Syndrome (Type A)

GC Biopharma Corp. announced that the European Medicines Agency has granted Orphan Drug Designation to its intracerebroventricular Enzyme Replacement Therapy candidate, GC1130A, designed for Sanfilippo Syndrome type A, developed in collaboration with Novel Pharma.